Since our T-ALL cell line (UP-ALL13) also harbors a R882 DNMT3A mutant, we evaluated in vitro the therapeutic efficacy of DOT1L inhibition by EPZ5676 [28]. The gene discussed is DOT1L; the disease is acute lymphoblastic leukemia.